Tasigna, the promoted medication name for its generic medication nilotinib, has been granted accelerated approval from the Food and Drug Administration (FDA) on June 7, 2010, to deal with newly diagnosed patients with Chronic Myelogenous Leukemia (CML).
Novartis, the Korean firm who made Tasigna, has had tens of thousands of suits filed since the drug hit the market in 2010. In 2013 Novartis compensated $390 million to illegal kickbacks to doctors who had been prescribing the medication to their patients, misbranding and false advertising.
Tasigna can lead to a fast start constriction of the blood vessels, and this has resulted in severe and even deadly complications in tens of thousands of individuals taking this medication.
Regrettably, patients have undergone multiple complications while taking the medication. A number of the most frequent side effects include:
- Severe abdominal or stomach pain
- Toe or joint pain
- Painful urination
- Swelling in the hands, ankles or feet
- Unusual or quick weight reduction
- Symptoms of high blood pressure; improved bleeding
- Indicators of liver disorder; persistent nausea, abdominal or stomach pain, yellowing of the skin or eyes, dark urine
- Limb amputation
If you’re having any of these symptoms immediately contact an experienced medical practitioner. People who have endured from Tasigna atherosclerosis, amputation or some other complications might qualify for compensation. Still, in doubt, you can refer to the source: Tasigna Atherosclerosis Lawsuit | Tasigna Perpheral Arterial Disease Lawsuit.
If a loved one is taking or have obtained Tasigna and suffered from acute complications such as limb amputation, atherosclerosis, peripheral vascular disorder or cardiovascular troubles, you and your family members might qualify for compensation.